Dependence on a small commercial portfolio
Revenue is concentrated in a few branded products, so any slowdown in prescription demand or access can materially affect results.
- Scope
- ZTlido, ELYXYB, GLOPERBA
- Materiality
- high
Scilex Holding Co
Scilex Holding Co is a U.S.-based biopharmaceutical company focused on non-opioid pain management and other specialty pharmaceutical products. Its commercial portfolio includes ZTlido, ELYXYB, and GLOPERBA, and it also develops product candidates such as SP-103, SP-104, and SEMDEXA through its operating subsidiaries and related collaborations.
−1 128,4 %
415,8 %
−1 236,4 %
−46,5 %
0.08
0.07
| % | |
|---|---|
| Commercial products | 100% Approved pharmaceutical products sold in the U.S., including ZTlido, ELYXYB and GLOPERBA. |
| Product candidates | 0% Development-stage programs for pain and related therapeutic areas, including SP-103, SP-104 and SEMDEXA. |
| Licensing and royalty arrangements | 0% Rights, royalties and supply arrangements tied to product commercialization and manufacturing partners. |
Scilex sells primarily into the U.S. pharmaceutical channel, where prescription products are purchased through...
- U.S. prescription drug distribution channelprimary
Wholesalers, regional distributors and pharmacies that buy and distribute ZTlido, ELYXYB and GLOPERBA.
- Physicians and prescribersprimary
Clinicians who prescribe the company's branded therapies for pain, migraine and related indications.
- Payors and formulary managersprimary
Commercial and government reimbursement decision-makers that affect access, rebates and net sales.
- Patientssecondary
End users of the company's prescription products, especially in non-opioid pain and migraine care.
- Development partnerssecondary
Counterparties in licensing, supply and joint venture arrangements that support pipeline development.
Scilex is primarily a United States business, with net revenue from product sales of ZTlido, ELYXYB and GLOPERBA...
- •United States is the core commercial market for all current products
- •Canada is relevant for ELYXYB territorial rights and royalties
- •Foreign manufacturing and supply partners support ZTlido and other products
- •Cross-border payments create foreign exchange exposure
- •Commercialization is concentrated in U.S. prescription drug channels
Scilex is focused on expanding commercial awareness and utilization of its marketed products while advancing its pain...
01
Grow branded product adoptionshort-term
Current revenue depends on prescription uptake and channel access for ZTlido, ELYXYB and GLOPERBA.
02
Advance pipeline programsmedium-term
Future value depends on clinical and regulatory progress for product candidates in pain and related indications.
03
Use partnerships and financing to fund developmentshort-term
The business model requires external capital and collaboration to support commercialization and R&D.
Scilex faces the typical risks of a specialty biopharmaceutical company: dependence on a small number of products,...
Financing and going-concern risk
The company expects to need additional capital to fund operations and development, which can dilute shareholders or constrain execution.
- Scope
- Equity, debt and strategic financing
- Materiality
- high
Clinical and regulatory development risk
Pipeline assets may not demonstrate efficacy, safety or approvability, which would limit future growth options.
- Scope
- SP-103, SP-104, SEMDEXA, Scilex Bio programs
- Materiality
- high
Supply chain and single-source dependency
Commercial supply and clinical materials are obtained from third-party and sometimes sole-source manufacturers, creating disruption risk.
- Scope
- Manufacturing, packaging, logistics
- Materiality
- high
Reimbursement and gross-to-net pressure
Rebates, chargebacks, returns and discounts reduce realized revenue and can vary with payer mix and channel dynamics.
- Scope
- Government and commercial payors
- Materiality
- high
Gross-to-net revenue adjustments
Affects reported revenue and receivables
Royalty liabilities
Affects cost of revenue and current liabilities
Inventory valuation
Affects gross margin and operating results
Fair value measurements
Affects non-cash gains/losses and balance sheet values
Intangible assets and in-process R&D
Affects asset values and future expense recognition
: 29.4.2026